These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34523767)

  • 41. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
    Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
    Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of immune checkpoint inhibitor therapy in patients with
    Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
    Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L).
    Garcia Campelo MR; Lin HM; Zhu Y; Pérol M; Jahanzeb M; Popat S; Zhang P; Camidge DR
    Lung Cancer; 2021 May; 155():68-77. PubMed ID: 33744781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
    Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
    J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
    [No Abstract]   [Full Text] [Related]  

  • 45. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
    Blackhall F; Kim DW; Besse B; Nokihara H; Han JY; Wilner KD; Reisman A; Iyer S; Hirsh V; Shaw AT
    J Thorac Oncol; 2014 Nov; 9(11):1625-33. PubMed ID: 25436797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
    Hirsh V; Cadranel J; Cong XJ; Fairclough D; Finnern HW; Lorence RM; Miller VA; Palmer M; Yang JC
    J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001.
    De Braud F; Deschler-Baier B; Morris JC; Worden F; Han Y; Kiiskinen U; Jen MH; Barker SS; Szymczak S; Gilligan AM
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.
    Zhu VW; Zhang SS; Zhang J; Swensen J; Xiu J; Ou SI
    J Thorac Oncol; 2021 Jul; 16(7):e51-e54. PubMed ID: 34154791
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.
    Walker MS; Wong W; Ravelo A; Miller PJE; Schwartzberg LS
    Clin Lung Cancer; 2018 Mar; 19(2):139-147. PubMed ID: 29103883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
    Leighl NB; Karaseva N; Nakagawa K; Cho BC; Gray JE; Hovey T; Walding A; Rydén A; Novello S
    Eur J Cancer; 2020 Jan; 125():49-57. PubMed ID: 31838405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
    Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
    Illini O; Hochmair MJ; Fabikan H; Weinlinger C; Tufman A; Swalduz A; Lamberg K; Hashemi SMS; Huemer F; Vikström A; Wermke M; Absenger G; Addeo A; Banerji S; Calles A; Clarke S; Di Maio M; Durand A; Duruisseaux M; Itchins M; Kääränien OS; Krenn F; Laack E; de Langen AJ; Mohorcic K; Pall G; Passaro A; Prager G; Rittmeyer A; Rothenstein J; Schumacher M; Wöll E; Valipour A
    Ther Adv Med Oncol; 2021; 13():17588359211019675. PubMed ID: 34178121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of selpercatinib in Chinese patients with advanced
    Zheng X; Ji Q; Sun Y; Ge M; Zhang B; Cheng Y; Lei S; Shi F; Guo Y; Li L; Chen L; Shao J; Zhang W; Gao M
    Ther Adv Med Oncol; 2022; 14():17588359221119318. PubMed ID: 36062046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selpercatinib Controls Central Nervous System Disease in Patients With NSCLC With RET Fusion.
    Zhao B; Xing H; Ma W
    J Thorac Oncol; 2023 May; 18(5):e51-e52. PubMed ID: 37087123
    [No Abstract]   [Full Text] [Related]  

  • 55. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.
    Wolf J; Garon EB; Groen HJM; Tan DSW; Gilloteau I; Le Mouhaer S; Hampe M; Cai C; Chassot-Agostinho A; Reynolds M; Sherif B; Heist RS
    Eur J Cancer; 2023 Apr; 183():98-108. PubMed ID: 36822130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
    van der Weijst L; Azria D; Berkovic P; Boisselier P; Briers E; Bultijnck R; Chang-Claude J; Choudhury A; Defraene G; Demontois S; Elliott RM; Ennis D; Faivre-Finn C; Franceschini M; Giandini T; Giraldo A; Gutiérrez-Enríquez S; Herskind C; Higginson DS; Kerns SL; Johnson K; Lambrecht M; Lang P; Ramos M; Rancati T; Rimner A; Rosenstein BS; De Ruysscher D; Salem A; Sangalli C; Seibold P; Sosa Fajardo P; Sperk E; Stobart H; Summersgill H; Surmont V; Symonds P; Taboada-Valladares B; Talbot CJ; Vega A; Veldeman L; Veldwijk MR; Ward T; Webb A; West CML; Lievens Y;
    Radiother Oncol; 2022 Nov; 176():127-137. PubMed ID: 36195214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage
    Goldman JW; Sholl LM; Dacic S; Fishbein MC; Murciano-Goroff YR; Rajaram R; Szymczak S; Szpurka AM; Chao BH; Drilon A
    Front Oncol; 2023; 13():1178313. PubMed ID: 37274265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase.
    Boucai L; Salas-Lucia F; Krishnamoorthy GP; Sherman E; Rudin CM; Drilon A; Bianco AC; Fagin JA
    JCO Precis Oncol; 2022 Jun; 6():e2100496. PubMed ID: 35704797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.